ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2003
Business Overview: The company develops, manufactures, and sells disposable medical connection products, primarily proprietary safe medical connector devices (CLAVE) for intravenous therapy, custom I.V. systems, and blood collection needles (Punctur-Guard). Sales are concentrated among medical product manufacturers (notably Abbott Laboratories) and independent distributors.

Key Financial Metrics

Additional Metrics:
- Gross Margin (Q2 2003): 54% (excluding other revenue), down from 59% in Q2 2002.
- Operating Income (Q2 2003): $6,055,000 (28% of net revenue).
- Effective Tax Rate (Q2 2003): 38.4%.
- Working Capital (June 30, 2003): $91,592,000.

Material Changes vs. Prior Period

• Revenue Decline (Q2): Total revenue decreased 6% to $21.3 million in Q2 2003 compared to Q2 2002. This was driven by a $4.6 million drop in CLAVE product sales, partially offset by $1.7 million in Punctur-Guard sales (from the Bio-Plexus acquisition) and $1.4 million in license/royalty income.
• Revenue Growth (YTD): Year-to-date revenue increased 19% to $52.1 million, driven by a 38% increase in custom I.V. systems sales, inclusion of Punctur-Guard sales, and non-product income.
• Customer Concentration: Abbott Laboratories accounted for 67% of Q2 2003 revenue. Sales to B. Braun Medical Inc. dropped to 1% (from 10% in Q2 2002) following the termination of their CLAVE supply agreement effective December 31, 2002.
• Profitability: Net income decreased 22% in Q2 2003 due to lower operating income. However, YTD net income increased 15% to $11.0 million.
• Acquisitions: The company acquired Bio-Plexus, Inc. in late 2002 (contributing $3.8M revenue YTD) and assets of two Italian I.V. manufacturers in June 2003 for $4.3 million.

Guidance, Outlook, and Risks

• Outlook: Management expects CLAVE unit and dollar sales to grow significantly in the second half of 2003 as Abbott and independent distributors replace inventory previously held by B. Braun. Gross margins for the full year 2003 are expected to be somewhat lower than the 57% recorded in 2002.
• Capital Expenditures: Estimated at approximately $12 million for 2003, including $4 million for facility expansion in Mexico and $6.8 million for molds and automated equipment.
• Share Repurchases: The company purchased $10.3 million of treasury stock in the first half of 2003 and an additional $5.0 million through August 5, 2003. A previously considered dividend was abandoned in favor of further stock repurchases.
• Risks:
  • Customer Concentration: Heavy reliance on Abbott Laboratories (67% of revenue) and the loss of B. Braun as a CLAVE distributor.
  • Competition: Price erosion in the CLAVE market due to competitors developing similar needleless connectors.
  • Legal: Ongoing patent litigation against B. Braun Medical, Inc. regarding the UltraSite connector.
  • Seasonality: Business typically diminishes in summer months (June-August).

Investor Verification Checklist

• Customer Concentration: Verify the stability of the Abbott Laboratories agreement and the extent to which independent distributors are successfully absorbing former B. Braun customers.
• Gross Margin Trends: Monitor the impact of the lower-margin Bio-Plexus product line and international price reductions on overall profitability.
• Capital Allocation: Assess the return on the $12 million planned capital expenditure and the strategic value of the Italian acquisition.
• Legal Proceedings: Track the status of the patent infringement lawsuit against B. Braun Medical, Inc.
• Inventory Levels: Review inventory write-off risks, particularly for components acquired through recent acquisitions or for products with shifting demand.